Morphotek Inc. Receives $2.7M in Funding from the National Institute of Allergy And Infectious Diseases (NIAID) to Develop Therapeutic Antibodies Against Biowarfare Agents

Published: Oct 03, 2007

EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced today that the company has received $2.7M in funding from the National Institute of Allergy and Infectious Diseases (NIAID) to support the preclinical development of fully human therapeutic monoclonal antibodies (mAbs) capable of neutralizing the toxic effects of Staphylococcal enterotoxin B (SEB) in vivo. The development project is a defense initiative in the fight against biowarfare agents

Back to news